Limposomes containing asiaticoside and the uses thereof
    2.
    发明申请
    Limposomes containing asiaticoside and the uses thereof 审中-公开
    含有积雪草苷的植物瘤及其用途

    公开(公告)号:US20060210619A1

    公开(公告)日:2006-09-21

    申请号:US10544088

    申请日:2004-01-30

    IPC分类号: A61K9/127 A61K31/704

    摘要: This invention belongs to the chemical field, which is related to the fields of pharmaceutical preparations and cosmetic, especially to asiaticoside-liposome and its use for preparing pharmaceutical preparations and cosmetic. In this invention, asiaticoside and lipid components are fused by heating or dissolved in organic solvents, then treated with the rotary thin layer evaporation technique, hydrated by adding aqueous solution under shaking to afford lipid dispersing aqueous solution, and then treated by using the technics of sonication, homogeneous emulsification, microjet and extruding filtration to enwrap asiaticoside in the middle of liposomal bilayer membranes to form the hydrophilic asiaticoside-liposome. Asiaticoside-liposome of this invention can enhance the stability, skin penetrability and hydrophilicity of asiaticoside, it can be used for the preparation of cosmetic and pharmaceutical preparations especially skin-penetrated pharmaceutical preparations, and it is more convenient and easy to prepare skin-penetrated pharmaceutical preparations and cosmetic containing asiaticoside.

    摘要翻译: 本发明属于化学领域,涉及药物制剂和化妆品领域,尤其涉及积雪草苷脂质体及其制备药物和化妆品的用途。 在本发明中,积雪草苷和脂质组分通过加热或溶解在有机溶剂中熔融,然后用旋转薄层蒸发技术处理,通过在振荡下加入水溶液进行水合,得到脂质分散水溶液,然后使用 超声处理,均匀乳化,微喷射和挤出过滤,在脂质体双层膜中间包裹积雪草苷,形成亲水性积雪草苷 - 脂质体。 本发明的积雪草苷 - 脂质体可以增强积雪草苷的稳定性,皮肤渗透性和亲水性,可用于制备化妆品和药物制剂,特别是皮肤渗透性药物制剂,并且更方便和容易地制备皮肤渗透的药物 含有积雪草苷的制剂和化妆品。

    Preparations of Taxanes for Intravenous Administration and the Preparation Method Thereof
    8.
    发明申请
    Preparations of Taxanes for Intravenous Administration and the Preparation Method Thereof 审中-公开
    静脉给药紫杉烷的制备及其制备方法

    公开(公告)号:US20110077291A1

    公开(公告)日:2011-03-31

    申请号:US12571176

    申请日:2009-09-30

    IPC分类号: A61K31/337 A61P35/00

    摘要: The present invention relates to the field of medical technology. More specifically, the present invention relates to a preparation of taxanes for intravenous administration, which consists of two parts: a drug solution and an emulsion. Said drug solution consists of paclitaxel or docetaxel, a pH regulator and a solvent for injection, wherein said solvent for injection is an organic solvent. Said emulsion includes a fat emulsion and is composed of oil for injection, an emulsifier, an antioxidant, an isotonic regulator, a stabilizer, a pH regulator and water for injection. When used, the drug solution at the clinical dosage can be added and mixed homogeneously in the emulsion to perform intravenous drip directly; or the drug solution at the clinical dosage can also be firstly added into the emulsion with no less than 5 times volume of the drug solution and then a predetermined amount of normal saline or glucose solution for injection is added to perform intravenous drip. The preparation of the present invention does not contain solubilizer and has advantages of little toxicity, safety, effectiveness, stability and economy. The fat emulsion is also used as a nutritional replenishment, thus achieving a better therapeutic effect. In addition, the normal saline or glucose solution for injection can be used to replace a considerable amount of the emulsion, which makes the preparation, therefore, not only cost-efficient, but also convenient for transportation and storage in practice.

    摘要翻译: 本发明涉及医疗技术领域。 更具体地说,本发明涉及用于静脉内给药的紫杉烷类的制剂,其由药物溶液和乳剂两部分组成。 所述药物溶液由紫杉醇或多西紫杉醇,pH调节剂和注射用溶剂组成,其中所述注射用溶剂为有机溶剂。 所述乳液包括脂肪乳剂,由注射用油,乳化剂,抗氧化剂,等渗调节剂,稳定剂,pH调节剂和注射用水组成。 使用时,可以将临床用量的药物溶液加入乳液中均匀混合,直接进行静脉滴注; 或者临床剂量的药液也可以首先加入不少于5倍体积的药物溶液的乳液中,然后加入预定量的生理盐水或注射用葡萄糖溶液进行静脉滴注。 本发明的制剂不含增溶剂,毒性小,安全性,有效性,稳定性和经济性好。 脂肪乳剂也用作营养补充剂,从而达到更好的治疗效果。 此外,用于注射的生理盐水或葡萄糖溶液可用于代替相当数量的乳液,这使得制剂不仅具有成本效益,而且在实践中也方便运输和储存。

    Drop pill for treating coronary heart disease and preparation thereof
    10.
    发明申请
    Drop pill for treating coronary heart disease and preparation thereof 审中-公开
    用于治疗冠心病的药丸及其制备

    公开(公告)号:US20110195136A1

    公开(公告)日:2011-08-11

    申请号:US13122800

    申请日:2009-09-30

    IPC分类号: A61K36/254 A61P9/00

    摘要: The present invention relates to a drop pill for treating coronary heart disease, comprising an active pharmaceutical ingredient (API), a matrix adjuvant, a plastifying adjuvant, propylene glycol and water. the API is prepared from Radix salvia miltiorrhira, Panax notoginseng and Borneol; the matrix adjuvant is erythritol; the plastifying adjuvant is one or more selected from the group consisting of polyethylene glycols, xylitol, lactitol, mannitol, glycerine, soluble amylum, gelatin, methyl cellulose, sodium carboxymethycellulose (CMC-Na), hydroxypropyl methylcellulose (HPMC), arabic gum, alginic acid, dextrin, cyclodextrin (CD), citrate, glycerol acetate, dibutyl sebacate, refined coconut oil and castor oil; Wherein, relative to the total weight of the drop pill, the API is 1˜40 wt %, the plastifying adjuvant 0˜10 wt %, the propylene glycol 1˜10 wt %, the water 0˜10 wt % and the balance is the matrix adjuvant. The drop pills of the present invention are safe and non-toxic, low moisture absorption and rapid dissolution.

    摘要翻译: 本发明涉及用于治疗冠心病的滴丸,其包含活性药物成分(API),基质佐剂,塑化佐剂,丙二醇和水。 API是由丹参,三七和冰片制成的; 基质佐剂是赤藓醇; 增塑佐剂是选自聚乙二醇,木糖醇,乳糖醇,甘露醇,甘油,可溶性淀粉,明胶,甲基纤维素,羧甲基纤维素钠(CMC-Na),羟丙基甲基纤维素(HPMC),阿拉伯树胶,海藻酸 酸,糊精,环糊精(CD),柠檬酸盐,乙酸甘油酯,癸二酸二丁酯,精制椰子油和蓖麻油; 其中相对于滴丸的总重量,API为1〜40重量%,增塑助剂0〜10重量%,丙二醇1〜10重量%,水0〜10重量%,余量为 基质佐剂。 本发明的滴丸是安全无毒,低吸湿性和快速溶解的。